-

CEO of Midwest Transplant Network Jan Finn Joins MTF Biologics Board of Directors

Finn will bring 30 years of organ procurement experience to the MTF Biologics Board

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing science, has announced that Jan Finn, President and Chief Executive Officer of the Midwest Transplant Network, has joined the organization’s Board of Directors.

“MTF Biologics is excited to welcome Jan onto our Board of Directors,” said Joe Yaccarino, President and Chief Executive Officer at MTF. “Jan brings nearly 30 years of organ procurement experience to the MTF Biologics Board. She is extremely passionate about our work to provide high-quality tissue grafts from donated human tissue and understands the positive impact that the gift of donation has on the lives of both recipients and donor families. We know that she will be an invaluable asset to our MTF team.”

As the President/Chief Executive Officer for Midwest Transplant Network (MTN), Ms. Finn is responsible for overseeing the executive leadership of a team that directs all organ and tissue donation operations in Kansas and Western Missouri. Under her leadership, MTN increased its donation rates and recovery of organs and tissues to record levels. MTN ranks in the top quartile nationally among other OPOs.

Ms. Finn currently serves on the Missouri Governor’s Advisory Council on Organ and Tissue Donation, the Legislative and Regulatory Affairs Committee for the Association of Organ Procurement Organizations (AOPO) and as a board member for the Gift of Life Foundation and the National Organ Donation Alliance. She is a past President of the North American Transplant Coordinators Organization (NATCO) and achieved certification from the American Board for Transplant Coordination as a Certified Procurement Transplant Coordinator (CPTC).

Ms. Finn began her career at St. John’s Regional Medical Center in Joplin, MO, working for 13 years as a Registered Nurse primarily in critical care. She holds undergraduate degrees from Missouri Southern State University and Pittsburg State University, as well as Master’s in Science from the University of Kansas. She was a member of the Sigma Theta Tau Nursing Honor Society and was credentialed as a CCRN by the American Association of Critical Care Nurses.

“I am delighted to join my friends at MTF Biologics as a member of their Board of Directors,” said Ms. Finn. “MTF Biologics remains a global leader in tissue and organ transplantation, and I look forward to working with the Board to help further MTF’s legacy of honoring donors and saving and healing lives.”

ABOUT MTF BIOLOGICS

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe. For more information, visit www.mtfbiologics.org.

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

MTF Biologics


Release Versions

Contacts

Kate Raley, 615-610-0202 or kate.raley@finnpartners.com

More News From MTF Biologics

MTF Biologics Announces New Funding Opportunities For 2026

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives through tissue and organ donation, transplantation, and research, today opened the call for proposals for its 2026 Allograft Research Grant Program. The 2026 program features the organization’s long-standing Innovation in Allografts Translational Research Grant Program and a new Dermal Allograft Innovation Grant, designed to accelerate the development of next generation technologies in allog...

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™

EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of orthobiologic solutions, today announced the launch of Summit Matrix™, an advanced synthetic bone graft designed to improve bone regeneration after orthopedic and spinal surgeries. Powered by NanoLift™ surface technology, Summit Matrix combines nanoscale to...

MTF Biologics’ AmnioBand® Membrane and AlloPatch® Pliable Confirmed as Covered Under Updated CMS Local Coverage Determinations

EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts and advancing the science of tissue transplantation, today announced that two of its aseptically processed allografts without terminal irradiation, AmnioBand® Membrane, an allograft placental matrix, and AlloPatch® Pliable an allograft dermal matrix, will remain among the 18 tissues covered under the newly updated Medicare Local Coverage Determinations (LCDs) for sk...
Back to Newsroom